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ABSTRACT 
Introduction. Blood perfusion of liver metastases can be non-invasively assessed by dynamic 
contrast enhanced magnetic resonance imaging (DCE-MRI). The aim of this study was to 
explore whether the ratio of hepatic arterial to total liver blood flow (Hepatic Perfusion 
Index – HPI) and the Area Under the enhancement Curve (AUC) of selected liver areas in 
patients with hepatic metastases from colorectal cancer treated with first-line 
chemotherapy could predict response and/or be a prognostic variable. 
Patients and Methods. Sequential liver DCE-MRI studies with morphological imaging 
reconstruction were performed in 43 consecutive patients at baseline and every 3 months 
during oxaliplatin-based first-line chemotherapy. Data about HPI of the whole liver, and AUC 
of metastatic and healthy areas were calculated at each time-point and compared both at 
baseline and sequentially during the treatment. 
Results. Baseline HPI and AUC values did not discriminate patients responsive to 
chemotherapy, nor those with better survival outcomes. HPI and AUC values at three 
months decreased significantly more in responders than non-responders. AUCs calculated 
from areas of the liver with or without neoplastic lesions varied consistently, being increased 
in progressing patients and decreased in responding patients. 
Discussion. Our results did not support the hypothesis of a predictive or prognostic role of 
HPI and AUCs calculated by DCE-MRI in liver metastatic CRC patients. However, reduced 
arterial blood flow in metastatic liver can be obtained by chemotherapy alone, without any 
anti-angiogenic agent; interestingly, HPI and AUC data suggest a possible relationship 
between tumor metabolism and entire liver perfusion. 
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INTRODUCTION 
Colorectal cancer (CRC) accounted for more than one million new cases and nearly 700.000 
deaths worldwide in 20121 and continues to be a relevant health and social problem. 
Hepatic metastases are a secondary site in approximately one third of the advanced disease 
patients2. Curative resection in selected patients has been proposed since early ’60s and 
became largely accepted in the ‘80s3, because a higher proportion of long-term survivors 
was observed with the surgical approach than in unselected series of patients treated with 
chemotherapy alone. Subsequently, in patients with unresectable hepatic metastases who 
obtained a response to chemotherapy, the subsequent hepatic surgery was associated with 
improved outcomes4. Consequently, medical oncologists are looking for active 
chemotherapy regimens that may give the patients the highest probability of tumor 
shrinkage. In this context, any predictive and/or prognostic variable that may help to identify 
the best therapeutic strategy would be clinically useful. 
The efficacy of chemotherapy depends not only on drug pharmacodynamics, but also on 
several other factors, such as the delivery of cytotoxic drugs through the tumor vasculature, 
drug uptake and retention in tumor cells, metabolic activation of pro-drugs, intrinsic 
chemosensitivity of tumor cells, catabolism and excretion of drugs, and by the total amount 
of drugs reaching tumor cells. Tumor blood flow in liver metastases and its changes 
following therapy is easily detectable by imaging techniques based on dynamic evaluation. 
Portal vein perfusion accounts for 60-80% of the total physiological liver blood supply, 
because only a limited proportion of blood supply to the normal liver comes through the 
arterial vessels, whereas in liver metastases the vascular supply derives predominantly from 
the hepatic artery. Consequently, liver with metastases has a higher arterial blood flow than 
normal hepatic tissue. The ratio of hepatic arterial to total liver blood flow (hepatic 
perfusion index, HPI) was firstly investigated using dynamic scintigraphy and was found to be 
abnormal in 88% and 58% of colorectal cancer patients with and without liver metastases, 
respectively5. Subsequently, HPI measurement methodology was adapted to dynamic CT, 
Doppler ultrasound, and finally to dynamic contrast-enhanced MR Imaging (DCE-MRI). HPI 
has been demonstrated to be a prognostic indicator of early liver recurrence, both in 
colorectal and in esophageal cancer patients6-8. In these studies, HPI was determined 
preoperatively in patients without metastases who underwent curative resection of the 
primary tumor, and patients with higher HPI presented shorter disease free and overall 
survival. In the metastatic setting hepatic basal HPI, measured by DCE-MRI, was increased in 
metastatic patients9 but no data are available about HPI changes following chemotherapy. 
Using DCE-MRI, the Area Under the enhancement Curve (AUC) is another parameter that 
can be used to assess the blood flow of selected areas of the liver. Decreases in AUC 
calculated from a region-of-interest (ROI) including the whole liver were demonstrated to 
correlate with tumor shrinkage and with a better time to progression in patients treated 
with standard chemotherapy plus bevacizumab10-11. 
However, in all the above-mentioned studies, imaging acquisition and reconstruction 
protocols did not allow a morphological evaluation of the liver, preventing any measurement 
of the metastases. Thus, in order to assess chemotherapy activity, additional CT or FDG-PET 
scan should be performed, with time consumption and additional costs. The aim of the 
present study was to prospectively evaluate the correlation between HPI and activity of first-
line chemotherapy in terms of response rate and survival, and to assess the potential role of 
AUC computation in normal and neoplastic hepatic areas by DCE-MRI, based on a protocol 
of image acquisition and reconstruction that in addition allows the morphological evaluation 
of the liver. 
 
PATIENTS AND METHODS 
Study design 
Patients with liver metastases from colorectal cancer, without contraindications for first-line 
chemotherapy, received an abdominal DCE-MRI at baseline, at 3 months, and eventually at 6 
months after the initiation of chemotherapy. Chemotherapy consisted in 5-fluorouracil (5-
FU) or capecitabine associated to oxaliplatin, started within one month from baseline DCE-
MRI. The study aimed to demonstrate an increase in Overall Response Rate (ORR) in patients 
with HPI values >0.3 (HPI high group) with respect to those with HPI ≤ 0.3 (HPI low group). 
Hypothesizing an ORR of 50% in HPI high group and of 25% in HPI low group, with α error of 
0.5 and β error of 0.2, the total number of patients to be enrolled was 106 (53 per arm). 
Patients gave their written consent and protocol was approved by our Local Ethical 
Committee. All the applied procedures followed the Helsinki Declaration. 
Treatment response was assessed repeating the same MRI technique and the best tumor 
response was classified according to the RECIST criteria version 1.112. 
DCE-MRI Method 
DCE-MRI was performed by the mean of a Philips Achieva 1,5T scanner, administering 
intravenously an extracellular contrast agent (gadobutrol 1mmol/mL - Gadovist®) at a total 
dose of 0.1 ml/Kg. Images were acquired through T1 weighted sequences and interpreted 
both morphologically and dynamically through a specific perfusion sequence. In particular, 
during the administration of gadobutrol at an injection rate of 4mL/sec, 16 dynamic phases 
were acquired. HPI and AUC were calculated using Philips ViewForum Perfusion T1 Software. 
HPI 
HPI represents the ratio of hepatic arterial to total liver blood flow and it is calculated from a 
time intensity curves derived from regions of interest (ROI) drawn manually in the aorta, 
liver and spleen. The ROIs in the liver were drawn to encompass the parenchyma and 
metastases but no major vessels. To estimate HPI, the “combined method” by White et al13 
was used. Arterial perfusion (Part) is calculated by dividing the peak gradient in the liver 
during arterial phase (gart) by the peak enhancement of the aorta (Iaorta), while portal 
perfusion (Pport) is derived from gradient after subtraction of the arterial component from 
the liver curve (g*port ), normalized by the enhancement of the aorta (Iaorta). On the basis of 
previous studies assessing HPI values in healthy subjects and in patients with clinically 
detected hepatic metastases in patients with CRC, values above 0.3 were considered as 
abnormal14-15. 
AUC 
While HPI is calculated considering the entire hepatic parenchyma, tumour metastases AUC 
was evaluated on a single metastatic nodule, followed throughout the entire study as a 
target lesion, drawing manually a ROI of 20 pixel in the hyperintense zone of the metastasis 
in order to exclude necrotic and not vascularized areas. Normal liver AUC was calculated 
drawing a 20 pixel ROI in apparently non-metastatic liver parenchyma. The AUC was 
calculated as the area under the time-intensity curve of the selected ROI over the entire 
procedure, normalized by the time of imaging acquisition expressed in seconds. Patients 
were then divided into two groups according whether their AUC values were greater than or 
less than or equal to 1000. This cut-off threshold was chosen as it represents the median of 
baseline normal AUC values of our patients. 
Survival evaluation 
Progression free survival and overall survival were estimated from the start of systemic 
treatment until disease progression or death or date of the last follow-up. The cut-off date 
for statistics analyses was March 15th, 2015. Patients not progressing or alive at the time of 
data analyses were censored at the time of the last follow-up examination. 
Statistical analyses 
HPI 
In order to explore the relationship between HPI and response to chemotherapy, patients 
were divided into two groups: responders versus non-responders (including progressive or 
stable disease). HPI values at baseline, 3 months and 6 months of the two groups were then 
compared using the Mann-Whitney U non-parametric test for unpaired variables. The same 
test was used to compare HPI variations along time of the two patient groups. Patients were 
then grouped according to HPI values at baseline (HPI<0.3 vs. HPI≥0.3). Proportions of 
responding patients in each group were compared using the chi-square test with Yates 
correction, if appropriate. Progression free survival and overall survival for each group were 
calculated and plotted using the Kaplan-Meier method and compared using the log-rank 
test. 
AUC 
Similarly to HPI, patients were grouped according to tumor response and AUC values and 
their variations along time were compared using the Mann-Whitney U test. Correlation 
coefficients (r) between tumor and normal AUC were calculated and validated according to 
the Spearman-Rank method. Progression free survival and overall survival for patients 
stratified according the cut-off value of 1000 were calculated and plotted using the Kaplan-
Meier method and compared using the log-rank test. Finally, patients were grouped 
according whether their tumor progressed at 3 months, responded or remained stable at 3 
months and then progressed at 6 months, or responded or remained stable at 6 months. 
Differences in AUC values between groups were compared and validated using the Kruskal-
Wallis analysis of variance. 
These statistical computations were performed using the SPSS for Windows Ver 22.0 and 
STATISTICA for Windows Ver 8.0 softwares. 
 
RESULTS 
Patients’ characteristics 
From March 2008 to September 2012, a total of 43 consecutive patients entered the study. 
Recruitment was prematurely stopped due to low enrollment rate. Patients’ characteristics 
are summarized in Table 1. All the patients but one had synchronous metastases. Males 
were predominant (25/43, 58.1%) and more than two-third of the primary tumors were 
located in the colon (30/43, 69.8%). Finally, the most frequent site of extra-liver metastases 
was the lung (20/43 patients, 46.5%). 
All patients received oxaliplatin combined with a fluoropyrimidine: 5-FU (FOLFOX scheme) in 
38 patients, or capecitabine (XELOX scheme) in 5 patients. Globally after the first 3 months 
of therapy, 29 patients had objective response (67.4%), 7 stable disease (16.3%), whereas 7 
progressed (16.3%). Among the 29 responding patients, 8 subsequently were treated with 
surgical resection (n=6) or radiofrequency ablation (n=2) for liver metastases. For the 
subsequent analyses, patients were grouped into two subgroups according to the clinical 
response: 29 responding patients vs 14 non-responding patients (7 with stable and 7 with 
progressive disease). 
At the data cut-off of March 15th, 2015, a total of 41 patients (95.3%) had experienced 
disease progression, with a median time to progression (TTP) of 9.8 months. At the same 
time point, after a median follow-up period of 35.5 months, 38 patients (88.4%) died, with a 
median overall survival (OS) of 20.8 months. 
HPI 
Data on HPI were obtained from 42 patients at baseline (in one patient it was not obtained, 
due to insufficient apnea time); from 41 patients at three months (one patient progressed 
and one was submitted to liver surgery before three months of therapy); and from 26 
patients at six months (seven patients progressed at three months, eight was submitted to 
liver surgery or local ablation of the metastases, and two failed to obtain HPI data due to 
technical reasons). 
Median (range) HPIs were: 0.249 (0.139-0.881) at baseline, 0.294 (0.127-0.590) at three 
months, and 0.241 (0.142-0.676) at six months. According to response to chemotherapy, 
median (range) HPIs at baseline were: 0.224 (0.147-0.881) for responders, and 0.253 (0.139-
0.563) for non-responders (p=0.78). According to the chosen HPI cut-off of 0.3, 18/26 
(69.2%) patients with low HPI values and 10/15 (66.6%) patients with high HPI values 
responded to chemotherapy (p=0.85). 
Median (range) HPIs at three months for patients according to clinical response were: 0.222 
(0.127-0.590) and 0.433 (0.182-0.527) for responders and non-responders, respectively 
(Figure 1; p=0.001). Overall HPI change between the two time points (baseline and three 
months) varied by a 10.3% (range -74.8%-+212.4%). The same figure was -5.9% (-74.8%-
+173.6%) and 60.6% (-7.6%-+212.4%) in responders and non-responders, respectively 
(p=0.003). 
Median (range) HPI at six months for responders was 0.215 (0.142-.458) vs 0.290 (0.157-
0.676) for non-responders (p=ns). No statistically significant differences neither in HPI values 
nor in their relative variations was demonstrated when patients were stratified according to 
tumor response between three and six month time points. 
Differences between groups in median TTP and OS did not reach statistical significance (TTP: 
11.0 vs 8.7 months; OS: 24.7 vs 14.9 months, for patients with basal HPI <0.3 and >0.3, 
respectively). 
 
AUC 
Data on liver metastasis AUC were obtained in 39 patients at baseline, in 36 patients at three 
months, and in 24 patients at 6 months. The same figures for normal liver AUC were: 39, 37, 
and 24 patients, respectively. Median image acquisition time was 285 seconds (range 180-
590 seconds). 
Median (range) lesioned AUCs were: 973.1 (275.2-2036.6) at baseline, 894.0 (449.6-2237.0) 
at three months, and 727.3 (373.7-1741.7) at six months. The same figures for healthy liver 
AUCs were: 688.4 (182.0-1441.7), 633.6 (355.4-2163.5), and 724.2 (418.4-1188.9), 
respectively. A direct correlation between tumor and normal liver AUCs was evident at each 
time point. The relative correlation coefficients (r) were: 0.67 at baseline (p<0.05), 0.65 at 
three months (p<0.05), and 0.47 at six months (p<0.05). 
Median (range) AUC change between baseline and 3 months were: -15.6% (-57.4% - 127.3%) 
in tumor areas and -14.8% (-59.7%-261.1%) in normal liver (correlation r=0.61, p<0.05). The 
same figures between 3 and 6 months were: -17.1% (-53.0%-85.9%) and 22.6% (-36.9%-
139.3%), respectively (correlation r=0.32, p=0.05). 
Tumor and normal liver tissue AUCs and their changes according to time points and 
response to chemotherapy are shown in Table 2. A difference in normal liver AUCs at three 
months was shown in responding vs. non-responding patients (absolute median values: 
591.9 vs 740.1, p=0.05; change: -17.9% vs -6.9%, p=0.05). 
When patients were grouped according to baseline AUC values using the cut-off value of 
1000 (<1000 AUC Low; >1000 AUC High), no difference in median TTP or in median OS was 
demonstrated (Table 3). Similar results were obtained when patients were divided using an 
arbitrary cut-off of 30% in AUC variation at three months compared to baseline. 
As an exploratory unplanned analysis, patients were further divided into three groups: 
patients progressing at three months (G1; 7 patients), patients not progressing at 3 months 
and progressing at 6 months (G2; 7 patients), and patients who were progression-free at 6 
months (G3; 29 patients). As far as normal liver AUC was concerned, in G1 median values 
increased at three months compared to baseline (551.2 vs 873.4, p= ns); in G2 decreased at 
3 months and remained stable at 6 months (917.8 vs 704.5 vs 654.5; p= 0.03); in G3 
decreased at 3 months and then slightly increased at 6 months (688.4 vs 591.6 vs 727.2; p= 
ns) (Figure 2A). When considering tumor tissue AUCs, median values increased in G1 (728.7 
vs 1091.5, p=0.04); remained stable in G2 (895.2 vs 928.0 vs 999.3; p=ns); and decreased in 
G3 (991.3 vs 833.7 vs 709.8; p=ns) (Figure 2B). 
 
DISCUSSION 
Analysis of DCE-MRI data is based on continuous image acquisition lasting several minutes 
and thus also during patient free-breathing. This condition, however, does not allow 
obtaining good anatomical image reconstructions due to motion artifacts, preventing size 
measurement. In our study we captured images under breath-hold conditions during 16 
dynamic phases. While this procedure did not affect HPI algorithm, the graph of signal 
intensity over time from which AUC is calculated was dependent from the total time of 
image acquisition, different for any single scan. In fact, scan total time ranged from 180 
seconds up to 590 seconds, with a variability of more than 220%. Then, in order to 
standardize data we normalized results dividing AUC for the total duration of the procedure, 
thus obtaining a median intensity value per second. It is worth to remember that the 
plasmatic half-life of the contrast agent is sufficiently long (1.8 hour)16 to prevent significant 
decrease of signal intensity in the time range of our acquisitions. 
Another possible bias that may lead to discordant results could be the difference in magnetic 
induction power of the scanners. As an example, Hirashima et al10 used a 3-Tesla whole-
body magnet, giving a higher signal performance than our scanner of 1,5 Tesla. Again, this 
difference is supposed to influence more AUC computations rather than HPI, as the latter is 
a proportion of data obtained from the same scanner. Finally, while HPI was calculated 
drawing the ROI including the entire liver, AUC data derived from an area chosen by the 
operator and this may contribute to jeopardize results. 
Considering the clinical impact of our study, ORR in the two HPI arms (HPI>0.3 vs HPI<0.3) 
could be calculated and was similar (66.2% vs 69.2%). Thus, we can conclude that the DCE-
MRI assessment in our limited series of patients did not support the hypothesis of a 
difference in ORR according to HPI at baseline, primary endpoint of the study. Moreover, the 
data of our study in metastatic colorectal cancer patients did not support the hypothesis of 
any correlation between the HPI changes during first line systemic chemotherapy, or AUCs of 
metastases or normal liver, and chemotherapy activity in terms of tumor response, TTP and 
OS. Nevertheless, interesting findings were reported including the reduction of arterial 
blood flow in metastatic liver generated by chemotherapy alone without adding any anti-
angiogenic agent. Moreover, HPI and AUC data suggest a possible control of the entire liver 
vasculature by substances directly produced and released into the bloodstream by tumor 
cells such as inflammatory cytokines. 
HPI data of our study agree with others already published17, with median baseline HPI value 
of 0.249, suggesting a reproducibility of this variable. Unfortunately, we failed to 
demonstrate a predictive role of baseline HPI because chemotherapy activity was not 
superior in those patients with higher HPI. Even though not statistically significant, a longer 
TTP and OS was observed in patients with HPI<0.3. A lower tumor aggressiveness expressed 
as a lower level of neo-angiogenesis could explain this observation. However, it would worth 
to verify this finding in a higher number of patients. HPI values decreased in responding 
patients whereas it increased in those non-responding. This observation is in line with the 
hypothesis that active chemotherapy impact on the arterial vasculature of the metastases, 
showing an anti-angiogenic activity. Furthermore, even though generally reduced, HPI did 
not significantly vary between 3- and 6-month time points in responding and non-
responding patients. This could be explained by the fact that progressive patients withdrawn 
the study at three months, and thus only those patients with clinical response or disease 
stabilization (i.e. those with at least a minimal antitumoral response to chemotherapy) 
continued up to 6 months of therapy, reducing sample size and smoothing differences 
between groups. 
Tumor and normal tissue AUCs were not correlated to chemotherapy activity or to survival. 
The above reported limitations and biases could have also accounted for these negative 
results. Our data do not support the use of this parameter in a routine clinical setting 
outside of an experimental trial. Both tumor and normal liver area AUCs increased in 
progressing patients, a slightly different trend was shown in those patients not progressing 
at 3 months and progressing at 6 months. In this patients tumor AUC remained stable 
throughout the observation time with an increasing trend, whereas normal liver AUC initially 
decreased and then remained stable. We believe this preliminary observation should be 
tested in a larger number of patients in order to verify whether variations of tumor AUC 
could be an early predictor of tumor progression, as this might be useful in the early switch 
to other active chemotherapeutic regimens. 
Despite these negative results, some interesting findings are worth of discussion. Firstly, it 
should be pointed out that in our study HPI reduction was observed following chemotherapy 
administration alone without the addition of an anti-neoangiogenetic agent as published 
elsewhere18. This finding raises several doubts about the interpretation of those studies in 
which reduction of perfusion parameters after administration of chemotherapy combined 
with anti-angiogenetics have been indicated as an efficacy index of this latter class of agents.  
Secondly we have shown a direct correlation between tumor and normal liver AUCs and 
their variations at each time point. This could be easily explained by external factors such as 
the total amount of contrast agent administered at each time. What was surprising is the 
correlation between both AUCs and tumor response. In progressing patients both tumor and 
normal tissue AUCs increased, whereas an inverse pattern was demonstrated in responding 
patients. This was unexpected as metastases have a higher arterial blood flow than normal 
liver due to the tumor neo-angiogenesis and thus only lesioned AUCs were supposed to be 
influenced by tumor response. This might suggest that growth factors, cytokines and 
inflammatory mediators produced by tumor cells or by tumor environment are able to 
influence the microcirculation of the liver. Furthermore, the correlation coefficient of 0.6 
between changes in tumor vs normal AUCs accounts for the observation of a decrease in HPI 
in responding patients, as in these patients arterial blood reduced more than portal blood 
flow. 
In conclusion, HPI could be easily assessed by routine DCE-MRI. While its putative prognostic 
role should be analyzed in a larger number of patients, its baseline values did not support 
the idea of a correlation between response to first line chemotherapy and patient outcomes. 
AUC assessed by an image acquisition protocol which permits morphological evaluation of 
the liver metastases did not demonstrate to be useful in predicting response rate and 
survival and it should be eventually reserved to the experimental setting. 
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Table 1. Patients’ characteristics. 
Patients  
No. of patients 
Median age years (range) 
Male (%) 
Female (%) 
  
Primary Tumor  
Colon (%) 
Rectum (%) 
Stage at diagnosis (Astler-Coller) 
                 A (%) 
                 B (%) 
                 C (%) 
                 D (%) 
Grade 
                 1 (%) 
                 2 (%) 
                 3 (%) 
                 unknown (%) 
  
Site of metastases other than liver  
Lung (%) 
Abdominal organs (%) 
Other (e.g. bone) (%) 
  
Type of chemotherapy administered  
Chronomodulated FOLFOX (%) 
FOLFOX (%) 
XELOX (%) 
  
No. of MRI with valid data  
Baseline (%) 
3 months (%) 
6 months (%) 
 
 
 
Table 2. Lesioned and Healthy liver AUC values and their variations according to time points 
and response to chemotherapy. 
 Responders Non Responders  
Absolute AUC values 
Median (range) 
      Baseline 
Lesioned 990.9 (275.2-2036.6) 856.1 (653.4-1197.4) ns 
Healthy liver 708.2 (182.0-1441.7) 659.0 (386.7-950.8) ns 
 
      3 Months 
Lesioned 881.3 (449.6-1520.9) 937.1 (540.5-2237.0) ns 
Healthy liver 591.9 (355.4-1147.6) 740.1 (387.3-1741.7) 0.05 
 
      6 Months 
Lesioned 713.0 (476.4-1409.1) 789.9 (373.7-1741.7) ns 
Healthy liver 727.2 (418.4-1188.9) 714.6 (594.1-1044.3) ns 
 
 AUC variation 
% (range) 
 
      3 Months From Baseline From Baseline  
Lesioned -15.6 (-57.4 - +97.4) -11.2 (-33.2 - +127.3) ns 
Healthy liver -17.9 (-59.7 - +223.1) -6.9 (-42.9 - +261.1) 0.05 
    
      6 Months From 3 Months From 3 Months  
Lesioned -9.5 (-53.0 - +79.0) -24.1 (-31.7 - +85.8) ns 
Healthy liver +25.3 (-36.9 - +139.3) +18.8 (-5.6 - +65.6) ns 
 
 
Table 3. Median survivals according to absolute baseline AUC values and their variation at 
three months in patients divided according to arbitrary values of 1000 (absolute AUC value) 
or +30% (AUC variation). AUC Low group represents patients with values lower than the 
relative cut-off. 
 TTP (months) OS (months)  TTP 
(months) 
OS (months)  
   
 AUC Low AUC High p AUC Low AUC High p 
Absolute AUC 
Lesioned 9.4 10.2 ns 24.4 16.2 ns 
Healthy liver 9.8 9.1 ns 24.4 8.2 ns 
 
AUC variation 
Lesioned 8.9 10.0 ns 14.3 33.3 ns 
Healthy liver 10.4 6.9 ns 18.2 19.3 Ns 
       
 
 
 
 
 
 
 
 
Figure legends 
 
Figure 1. HPI values at three months in patients stratified according to the response to 
therapy. (PD = Progressive Disease; SD = Stable Disease; PR = Partial Response; CR = 
Complete Response). 
 
 
Figure 2. Healthy (A) and Lesioned (B) liver AUCs at baseline, 3 months and 6 months (when 
the case) for patients stratified according whether they progressed at 3 months (P), the did 
not progressed at 3 months and progressed at 6 months (No P  P), or they never 
progressed (No P). Squares are median values, boxes are quartiles, lines are extremes. 
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